跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
REBLOZYL
Authorized
STANDARD
REBLOZYL
bristol-myers squibb canada
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
62a6b86b1e4b781e
Company
bristol-myers squibb canada
Type
Standard
Approval Details
Approval Id
62a6b86b1e4b781e
Drug Approval Canada Name
REBLOZYL
Product Name
REBLOZYL
Status
Marketed
Status Date
2025-02-19
Original Market Date
2020-11-23
Din
02505568
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
20:04.00
Atc Original
B03XA06 LUSPATERCEPT
Atc Name
b 03 xa 06
Aig Number
0162498002
Company Name
bristol-myers squibb canada
Company Address
2344 Boul. Alfred-Nobel, Suite 300, St-Laurent, Quebec, Canada, H4S 0A4
Active Ingredients
LUSPATERCEPT
75 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
62a6b86b1e4b781e
Type
Standard
Back to Health Canada Approvals
REBLOZYL - Health Canada Drug Approval Details